Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 12/20 | 0.40 |
| ▸ | IKBKB | O14920 | 4/20 | 0.36 |
| ▸ | JAK2 | O60674 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | NPR3 | P17342 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280680 | 1.00 | CHEK1 (0.40) | CHEK1IKBKBJAK2JAK3NPR3 | |
| SCHEMBL2280687 | 1.00 | CHEK1 (0.40) | CHEK1IKBKBJAK2JAK3NPR3 | |
| SCHEMBL2341718 | 0.93 | CHEK1 (0.40) | CHEK1IKBKBJAK2JAK3NPR3 | |
| SCHEMBL2341719 | 0.93 | CHEK1 (0.40) | CHEK1IKBKBJAK2JAK3NPR3 | |
| SCHEMBL2341716 | 0.93 | CHEK1 (0.40) | CHEK1IKBKBJAK2JAK3NPR3 | |
| SCHEMBL2348039 | 0.92 | CHEK1 (0.41) | CHEK1IKBKBJAK2JAK3MEN1 | |
| SCHEMBL2348033 | 0.92 | CHEK1 (0.41) | CHEK1IKBKBJAK2JAK3MEN1 | |
| SCHEMBL2348042 | 0.92 | CHEK1 (0.41) | CHEK1IKBKBJAK2JAK3MEN1 | |
| SCHEMBL2280263 | 0.90 | CHEK1 (0.49) | CHEK1IKBKBJAK2JAK3MEN1 | |
| SCHEMBL2280269 | 0.90 | CHEK1 (0.49) | CHEK1IKBKBJAK2JAK3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078007-B1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-08-31 | — | — | EP | claimed |
| US-8003695-B2 | IKK-beta serine-threonine protein kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-08-23 | — | — | US | claimed |
| US-20100087515-A1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | Chroma Terapeutics Ltd (GB) | 2010-04-08 | — | — | US | claimed |
| EP-2078007-B1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087515-A1 | IKK-BETA SERINE-THREONINE PROTEIN KINASE INHIBITORS | IRAK3, IKBKE, IRAK1 | CHEK1 204/4885IKBKB 5/4885JAK2 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.